In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Placing Value on FDA's Priority Review Vouchers

Executive Summary

The ability of priority review vouchers to stimulate research for neglected diseases of the developing world hinges on the vouchers having tangible value. What's the worth of a priority review voucher on the market and how does that value change depending upon the situation?
Advertisement

Related Content

Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval
Novartis Coartem NDA May Lead to First Priority Review Voucher
Treat and Trade: The New Priority Review Voucher Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel